Related Experiment Video

Updated: Aug 27, 2025

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

2.9K

Novel Synergistic Combination of Pamidronate and Temozolomide for Breast Cancer Therapeutics

Nida Syed1, Amber Ilyas1, Basir Syed2

  • 1Dr. Zafar H. Zaidi Center for Proteomics, University of Karachi, Karachi 75270, Pakistan.

Current Cancer Drug Targets
|September 26, 2022
PubMed
Abstract

Insights

Pamidronate (PAM) and Temozolomide (TMZ) combination therapy shows significant anti-cancer effects against breast cancer cells. This synergistic treatment downregulates key Mevalonate pathway genes and proteins, offering a promising new strategy for breast cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Human breast cancer presents a significant global health challenge with high mortality rates.
  • Carcinogenesis involves various cellular signaling pathways, including the Mevalonate (MVA) pathway, which regulates downstream cellular growth.
  • Inhibiting the MVA pathway has demonstrated therapeutic benefits in multiple cancer types.

Purpose of the Study:

  • To investigate the efficacy of an adjuvant therapy combining Pamidronate (PAM), an MVA inhibitor, with Temozolomide (TMZ), an alkylating agent, for treating breast cancer.
  • To explore the molecular mechanisms underlying the combined treatment's effects on breast cancer cells.

Main Methods:

  • Differential gene expression analysis using RT-qPCR.
  • Proteomic analysis employing two-dimensional gel electrophoresis and mass spectrometry.
  • Evaluation of cytotoxic effects of combination therapy versus single-agent treatments.

Main Results:

  • The combination of PAM and TMZ exhibited a more pronounced cytotoxic effect on breast cancer cells compared to individual treatments.
  • Significant downregulation (p<0.05) of MVA pathway regulatory genes (FDFT1, FDPS, KRAS) was observed in cells treated with the combination therapy.
  • Differential proteomic analysis revealed decreased expression of GFAP, PPA1, and TRIM68 proteins following synergistic treatment, contrasting with their upregulation in other cancers.

Conclusions:

  • The combination of PAM and TMZ effectively suppresses breast cancer cell growth.
  • This novel therapeutic regimen holds potential as an improved treatment strategy for breast cancer, warranting further clinical investigation.
Keywords:
MVA pathwayPamidronatebreast cancerpamidronate (PAM)proteomicssynergistic effect

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.3K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.5K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
4.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
643
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K